Agoura Hills, 91301, CA,
United States
Oncotelic Technographics
Discover the latest software purchases and digital transformation initiatives being undertaken by Oncotelic and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 30 Oncotelic employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.
During our research, we have identified that Oncotelic has purchased the following applications: IBM Clinical Development for Clinical Trial Management in 2020, Google Tag Manager for Tag Management in 2021 and the related IT decision-makers and key stakeholders.
Our database provides customer insight and contextual information on which enterprise applications and software systems Oncotelic is running and its propensity to invest more and deepen its relationship with IBM , Google or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.
We have been analyzing Oncotelic revenues, which have grown to $1.0 million in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Oncotelic intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.
ERP Services and Operations
Vendor |
Previous System |
Application |
Category |
Market |
VAR/SI |
When |
Live |
Insight |
|---|---|---|---|---|---|---|---|---|
| IBM | Legacy | IBM Clinical Development | Clinical Trial Management | ERP Services and Operations | n/a | 2020 | 2020 |
In 2020, Oncotelic implemented IBM Clinical Development, a Clinical Trial Management application, to support a Phase II trial of OT-101 for COVID-19 in the United States. The selection was announced in June 2020 when Mateon granted its Oncotelic subsidiary access to IBM Clinical Development at no cost to provide cloud EDC and clinical operations capabilities for the trial.
IBM Clinical Development was provisioned as a cloud hosted clinical data platform, with configuration centered on electronic data capture workflows, inferred use of ePRO for patient reported outcomes, and remote monitoring and reporting features to support decentralized participant oversight. The implementation emphasized structured case report form design, database build for Phase II endpoints, and remote access controls consistent with clinical operations and data management practices.
Operational coverage focused on Oncotelic clinical operations and data management teams supporting the Phase II OT-101 study within the United States. Governance attention was placed on protocol aligned CRF configuration, remote monitoring workflows, and centralized reporting to coordinate site and sponsor interactions, with the system used to streamline data capture and remote patient monitoring for the clinical trial.
|
CRM
Vendor |
Previous System |
Application |
Category |
Market |
VAR/SI |
When |
Live |
Insight |
|---|---|---|---|---|---|---|---|---|
| Legacy | Google Tag Manager | Tag Management | CRM | n/a | 2021 | 2021 |
|
| First Name | Last Name | Title | Function | Department | Phone | |
|---|---|---|---|---|---|---|
| No data found | ||||||
| Date | Company | Status | Vendor | Product | Category | Market |
|---|---|---|---|---|---|---|
| No data found | ||||||